ScotiaDerm

ScotiaDerm is a clinical-stage biotechnology company based in Halifax, Canada, specializing in the development of innovative topical therapies for chronic inflammatory skin diseases. The company focuses on bridging the gap between clinical research and commercial treatment for conditions such as atopic dermatitis and psoriasis. Led by prominent dermatological researchers from Dalhousie University, ScotiaDerm leverages deep clinical expertise to advance proprietary formulations through rigorous clinical trials. Its lead candidate, SD-01, is a non-steroidal topical formulation designed to provide effective anti-inflammatory relief with a favorable safety profile compared to existing corticosteroid treatments. The company's mission is to improve the quality of life for patients suffering from debilitating skin conditions through targeted, science-driven dermatological solutions.